Schatzberg Alan F
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Stanford, CA 94305-5797, USA.
Psychiatr Clin North Am. 2015 Sep;38(3):379-93. doi: 10.1016/j.psc.2015.05.009.
Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures. Lastly, possible solutions for improving the likelihood of the success of antidepressant/anxiolytic agents are discussed.
抗抑郁药和抗焦虑药的研发在很大程度上陷入了停滞。本文综述了当前开发镇静剂和抗焦虑药的新方案。文中讨论了这些方案的生物学基础以及近期的研究结果。同时回顾了所遇到的问题。接着讨论了最近宣布失败的其他抗抑郁药项目，旨在找出可能解释其失败的共同因素。最后，探讨了提高抗抑郁药/抗焦虑药成功可能性的可能解决方案。
